 

Active ingredient: Allopurinol 

 

Form/Route: Tablets/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 

Design: Single-dose, two-way crossover in vivo 

Strength: 300 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional Comments: 




______________________________________________________________________________ 

 

2. Type of study: Fed 

Design: Single-dose, two-way crossover in vivo 

Strength: 300 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional Comments: 




______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Allopurinol in plasma 

 

Bioequivalence based on (90% CI): Allopurinol 

 

 

Waiver request of in-vivo testing: 100 mg based on (i) acceptable bioequivalence studies on the 
300 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) 
acceptable in vitro dissolution testing of all strengths. 

 

 

Dissolution test method and sampling times: Please note that Dissolution Method Database 
is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please 
find the dissolution information for this product at this website. Please conduct comparative 
dissolution testing on 12 dosage units each of all strengths of the test and reference products. 
Specifications will be determined upon review of the application. 

 

 


